drugset
drugset / Trial / NCT05133440

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

NCT05133440 ↗

Phase 2 Completed 12 enrolled Memorial Sloan Kettering Cancer Center
RandomizedParallel-groupOpen-labelTreatment

Summary

Participants will either receive treatment with standard SBRT and the study drug Radium (Ra-223) dichloride, or standard SBRT alone.

Timeline

Start
2021-11-12
Primary completion
2026-04-27
Completion
2026-04-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Ra223 Unknown 0.055 mbq/kg —

Indications

prostate cancer